

Phospholipase A₂ Regulation of Lipid Droplet Formation

Carlos Guijas,^{1,2} Juan P. Rodríguez^{1,3}, Julio M. Rubio,^{1,2}

María A. Balboa,^{1,2} and Jesús Balsinde^{*,1,2}

¹*Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Valladolid, 47003 Valladolid, Spain*

²*Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain*

³*Laboratorio de Investigación en Proteínas, Facultad de Ciencias Exactas y Naturales y Agrimensura, Universidad Nacional del Nordeste, 3400 Corrientes, Argentina*

*Corresponding author. Phone, +34-983-423-062; Fax, +34-983-184-800;

e-mail: jbalsinde@ibgm.uva.es

Keywords: Phospholipase A₂; Lipid Droplet; Arachidonic Acid; Lipid Mediators; Inflammation.

Running Title: Phospholipase A₂ and Lipid Droplets

Abstract

The classical regard of lipid droplets as mere static energy-storage organelles has evolved dramatically. Nowadays these organelles are known to participate in key processes of cell homeostasis, and their abnormal regulation is linked to several disorders including metabolic diseases (diabetes, obesity, atherosclerosis or hepatic steatosis), inflammatory responses in leukocytes, cancer development and neurodegenerative diseases. Hence, the importance of unravelling the cell mechanisms controlling lipid droplet biosynthesis, homeostasis and degradation seems evident. Phospholipase A₂s, a family of enzymes whose common feature is to hydrolyze the fatty acid present at sn-2 position of phospholipids, play pivotal roles in cell signaling and inflammation. These enzymes have recently emerged as key regulators of lipid droplet homeostasis, regulating their formation at different levels. This review summarizes recent results on the roles that various phospholipase A₂ forms play in the regulation of lipid droplet biogenesis under different conditions. These roles expand the already wide range of functions that these enzymes play in cell physiology and pathophysiology.

Abbreviations: LD: lipid droplet; PLA₂: phospholipase A₂; cPLA₂: cytosolic phospholipase A₂; iPLA₂: Ca²⁺-independent phospholipase A₂; sPLA₂: secreted phospholipase A₂; Lp-PLA₂: lipoprotein-associated PLA₂; PC: phosphatidylcholine; lysoPC: lysophosphatidylcholine; PE: phosphatidylethanolamine; lysoPE: lysophosphatidylethanolamine; PI: phosphatidylinositol; PA: phosphatidic acid; lysoPA: lysophosphatidic acid; TAG: triacylglycerol; CE: cholesteryl esters; AA: arachidonic acid; HCV: hepatitis C virus; LDL: low-density lipoprotein; ox-LDL: oxidized low-density lipoprotein; PAF, platelet-activating factor.

1. Introduction

Lipid droplets (LDs) are organelles present practically in all cell types. All LDs are spherical particles with a surface composed of a phospholipid monolayer decorated by a variety of proteins that encases a neutral lipid core consisting primarily of triacylglycerol (TAG) and cholesteryl esters (CE). Over a hundred distinct molecular species of phospholipids have been identified in the LD phospholipid monolayer [1-3]. In mammalian cells and yeast, phosphatidylcholine (PC) is the most abundant phospholipid, comprising up to 60% of total phospholipid content, followed by phosphatidylethanolamine (PE) (24%) and phosphatidylinositol (PI) (8%) [4].

Specific populations of proteins that are more or less tightly bound to the LD surface play different roles in LD biogenesis, trafficking and mobilization. Prominent proteins of mammalian LDs are the so-called PAT family, which includes perilipin, adipophilin and TIP47 (Tail-Interacting Protein of 47 KDa) [5]. Additionally, numerous enzymes related to lipid metabolism have been described, including adipose triglyceride lipase, hormone-sensitive lipase, CGI-58 (comparative gene identification-58) [6,7], CTP:phosphocholine cytidylyltransferase [8], lipin-1 [9,10], and, group IVA phospholipase A₂, (cytosolic phospholipase A₂ α , cPLA₂ α) [11,12].

LD biogenesis needs to be contemplated in the context of the synthesis and turnover of its major components: TAG and CE. These neutral lipids can be formed using fatty acids arising from various origins, i.e. exogenous sources, other cellular compartments, or via stimulation of the *de novo* fatty acid biosynthetic pathway. Once synthesized, the neutral lipids are first clamped between the two layers of the endoplasmic reticulum membrane. Phospholipid bilayers can accommodate about 3% TAG or 5% CE, on a molar basis, before the neutral lipid phase separates to form spherical domains of about 25–28 nm diameter that remain sandwiched between the

bilayer leaflets [13]. Such TAG microdomains are probably the precursors of the LD that are released from the endoplasmic membrane to the cytosol; however there is much controversy about the origin of the LDs and various hypotheses have been put forward to explain the experimental evidence. These have recently been reviewed in detail [14].

LD number and size varies dynamically from one cell type to another, or among cells of the same population, and the activation state of the cells appears to be a key factor [15,16]. It has recently been shown in hepatocytes that the LDs within a given cell or among cells of the same tissue show a remarkable heterogeneity [17]. Thus it has been suggested that the existence of cells containing high lipid levels within a cell population could potentially reduce lipotoxicity to the average cell without impairing overall lipid homeostasis [17].

The impressive number of recent studies and review articles dealing with LDs, illustrates the dramatic change in the way these organelles are currently perceived. From being regarded as mere storage depots for metabolic fuel and membrane-building blocks, LDs are now recognized as key players in the cellular regulation of lipid homeostasis, signaling, protein sorting, extra- and intracellular trafficking, and gene transcription regulation [14,18,19]. Furthermore, the formation of LDs may also constitute a sign of stress and of apoptotic cell death [20].

2. Phospholipase A₂ enzymes

2.1. Classification

Phospholipase A₂ (PLA₂) enzymes constitute an heterogeneous group of proteins which have been systematically classified according to sequence homology criteria. The latest update to this classification, published in 2011 [21], included 16 groups, most of them with several subgroups, comprising more than 30 proteins (Table I). Only PLA₂s whose

nucleotide sequence has been determined are included in the classification. Although the common feature of all these proteins is that they possess PLA₂ activity, that is, they hydrolyze the fatty acid at the sn-2 position of glycerophospholipids, recent additions to the classification display very low PLA₂ activity or no PLA₂ activity at all. Also some members of the PLA₂ superfamily frequently display other activities in addition to PLA₂, such as phospholipase A₁, lysophospholipase, transacylase or TAG lipase [21,22].

There is an alternative PLA₂ classification, sometimes more useful, which groups these enzymes into 6 major classes on the basis of biochemical commonalities and/or cell regulation properties. These are the Ca²⁺-dependent cytosolic PLA₂s (cPLA₂), the Ca²⁺-dependent secreted PLA₂s (sPLA₂), the Ca²⁺-independent cytosolic PLA₂s (iPLA₂), the platelet-activating factor acetyl hydrolases (PAF-AH), the lysosomal PLA₂ (LPLA₂) and the adipose-specific PLA₂ (AdPLA) [21,22]. Note that despite its evident usefulness, this classification is not devoid of inconsistencies, e.g. despite being referred to as secreted enzymes, some sPLA₂s may indeed act inside the cells, cPLA₂γ is grouped among the Ca²⁺-dependent cytosolic enzymes despite it being completely Ca²⁺-independent, etc.

Of these classes, the first two have been repeatedly implicated in AA mobilization leading to eicosanoid synthesis in response to a variety of immunoinflammatory stimuli [23-25]. The pivotal enzyme is the cPLA₂α, an enzyme that exhibits marked preference towards AA-containing phospholipids [26]. Some sPLA₂ enzymes, i.e. those from groups IIA, V and X may amplify the cPLA₂α-mediated AA release and eicosanoids production either directly by effecting the AA release themselves or by modulating the extent of cPLA₂α activation [27-29]. cPLA₂α-

independent AA release and eicosanoid response by group V and group X sPLA₂s acting directly on the extracellular surface is also known to occur in some instances [30]. There is no clear evidence that iPLA₂ enzymes play major effector roles in AA mobilization in response to most stimuli although in some circumstances and in response to specific agonists, these enzymes may serve such role [21,31]. iPLA₂ enzymes may also participate in the formation of cellular AA pools by providing lysophospholipid acceptors for AA reacylation reactions [32-34].

The presence of PLA₂ enzymes in practically all cells and tissues examined stresses the important roles they play in many physiological and pathophysiological processes. A number of comprehensive reviews have recently been published covering various aspects of PLA₂ biochemistry, including structure, catalysis, cellular regulation and physiological/pathophysiological functions [21,22,35-37], and the reader is kindly referred to them for further details.

2.2. PLA₂ and lipid droplets

Recent evidence suggests that LDs may function as intracellular sites for eicosanoid biosynthesis. LDs of different cell populations such as eosinophils, macrophages, neutrophils or mast cell avidly incorporate exogenous AA. Lipid analyses of LDs isolated from blood leukocytes have shown that AA is mainly esterified in phospholipids [38], whereas in mast cells and macrophages it is found primarily in neutral lipids [39]. Whether these differences in localization have a physiological consequence or are due to other factors, i.e. differences in the total content of AA present in the cells [40], is unknown.

Several enzymes implicated in the biosynthesis of eicosanoids have been found associated with LDs under activation conditions, including cPLA₂α [11,12].

Extracellular signal-regulated kinases-1 and -2, which can phosphorylate and activate cPLA₂α, have also been found in LDs [41], as well as the major AA-converting enzymes 5-lipoxygenase, 15-lipoxygenase, 5-lipoxygenase-activating protein, and cyclooxygenase-2 [15,42]. Lipin-1, a phosphatidic acid phosphatase that acts as an upstream regulator of cPLA₂α and attendant AA release and eicosanoid production [43-45], has also been found in LDs [9].

Aside from the role of LDs as platforms for compartmentalized regulation of AA mobilization and eicosanoid synthesis, various PLA₂ forms have also emerged as critical regulators of the biogenesis of LDs. PLA₂s may act at several levels, namely (i) as providers of free fatty acids from membrane phospholipids for the synthesis of neutral lipids [46-48], (ii) as modifiers of phospholipid-containing particles to facilitate their uptake and internalization by cells [49,50], (iii) as generators of metabolites that may control LD formation [51], and (iv) as direct regulators of the formation of the organelle [52-54].

3. cPLA₂

To date, 6 cPLA₂s have been identified in mammals and classified as group IV PLA₂s. These enzymes possess a high molecular weight (61-114 kDa) and, with the exception of cPLA₂γ, a C2 domain at their N-terminal region which binds Ca²⁺, allowing these enzymes translocate to intracellular membranes. Contrary to sPLA₂s, only micromolar concentration of Ca²⁺ are required for activity [21,22,26].

The best characterized of these enzymes is group IVA PLA₂ or cPLA₂α, which may further require phosphorylation by several kinases and association with phosphoinositides or ceramide-1 phosphate for full activation [55]. After stimulation of the cells with a variety of agonists, the enzyme translocates to multiple intracellular

compartments, including the nuclear envelope, Golgi, endoplasmic reticulum, phagosomes, plasma membrane and LDs [11,12,22,26,35,56].

3.1. Mechanisms of LD biogenesis involving cPLA₂α

The most accepted, albeit not the only, hypothesis for the biogenesis of LDs proposes that these organelles are generated in between the two leaflets of the smooth endoplasmic reticulum, and bud out to the cytoplasm after a very tightly regulated process which includes generation of free fatty acids, thioesterification of the latter with CoA, neutral lipid synthesis, remodeling of endoplasmic reticulum membrane phospholipids, and synthesis of new phospholipids and LD-associated proteins [14]. While various cellular PLA₂s may contribute to generate the pool of free fatty acids initially needed for LD synthesis, strong evidence is emerging that the PLA₂ form that is centrally involved in the remodeling of endoplasmic reticulum phospholipids and LD expansion processes involving deacylation/reacylation reactions is the cPLA₂α [14,57,58] (Fig. 1).

DGAT and ACAT, the terminal enzymes for TAG and CE biosynthesis, are homogeneously distributed along the endoplasmic reticulum and are able to synthesize a large amount of neutral lipid in response to different situations such as external lipid overload, endoplasmic reticulum stress or cellular activation [59]. Initially, the neutral lipids formed can be accommodated into the hydrophobic space between the two leaflets of the endoplasmic reticulum up to a point where the two leaflets of the endoplasmic reticulum separate, and TAG and CE become sequestered inside a phospholipid monolayer to form a cytoplasmic LD [13,14,60]. Small amounts of phospholipid are required for LD monolayer expansion, but a tight regulation of the

ratio of phospholipid to neutral lipid in LDs is essential to maintain the round shape and biophysical properties of the nascent organelle [4].

By controlling the ratio of phospholipid to lysophospholipid in the endoplasmic reticulum and Golgi complex, PLA₂ enzymes determine the shape and curvature of the membranes of these organelles, and allow the proper execution of a number of events such as membrane tubule formation in the Golgi, cargo delivery from the endoplasmic reticulum to the Golgi, or membrane fusion processes [61-63]. Thus cPLA₂α may exert similar regulatory effects on the membranes of the smooth endoplasmic reticulum at the time that neutral lipid concentration reaches its critical concentration in between the leaflets. As a matter of fact, inhibition of cPLA₂α activity by various means does not change the cellular levels of neutral lipid but results in distorted endoplasmic reticulum membranes with tubulovesicular structure [52].

The nascent LD needs a local positive membrane curvature in the endoplasmic reticulum membrane baseline to grow up. The normal endoplasmic reticulum membrane is composed primarily of phosphatidylcholine (PC), which presents a cylindrical shape and generates a neutral curvature, and to a lesser extent, phosphatidylethanolamine (PE), which generates a slight negative curvature [4, 18]. Biophysical determinations have unveiled that accumulation of lysophospholipids with a wedge shape conformation such as lysoPC, lysoPE and, especially, lysoPA, generates a local positive membrane curvature, beneficial in terms of nascent LD budding [4,14,18,58,64-66]. Since lysophospholipids are generated by PLA₂s, the key role that cPLA₂α appears to play in these stages of LD formation can be explained [20,46,52-54] (Figure 1).

Once the required positive curvature at the LD baseline is generated, more neutral lipids can be accommodated inside the phospholipid monolayer, either

synthesized in the endoplasmic reticulum or directly in the forming LD, where the enzymes necessary for TAG and CE biosynthesis are localized. This is accompanied by the synthesis of phospholipid to maintain the appropriate phospholipid to neutral lipid, in a process occurring via both the *de novo* phospholipid biosynthesis and fatty acid recycling by the Lands pathway [8,14], a route in which PLA₂ enzymes are essential [36,55]. In this regard, the PC molecules on the LD surface are particularly enriched in monounsaturated fatty acids, something that does not apply to the PC molecules at the endoplasmic reticulum [4], and highlights the important role of phospholipid fatty acid recycling to achieve the proper phospholipid composition of LDs at this stage.

Once the LD buds from the endoplasmic reticulum membrane, conversion of the conical lysophospholipids into cylindrical phospholipids is necessary to establish a neutral curvature that confers stability and protects the hydrophobic core from lipolysis. In this stage, participation of lysophospholipid acyltransferases using acyl-CoA as donor are the essential enzymes [14,58]. Some of these enzymes have also been found associated with LDs [4,67].

Finally, before LD is completely formed, a local negative curvature in the baseline of the endoplasmic reticulum membrane is required [14,58]. This is promoted by the accumulation of PA, which induces a spontaneous strong negative curvature [18,68] (Fig. 1). PA is thought to be generated primarily by phospholipase D [69,70], but achieving the optimal levels of this metabolite may also involve the participation of the PA phosphatase lipin-1 [9,10]. Inhibition of lipin-1 results in LD fragmentation and reduced size and number of LDs without changes in total TAG content [9,10]. While some of these effects are likely due to modification of cellular PA levels, lipin-1 is also known to regulate cPLA₂ α activation [9], which raises the possibility that the latter enzyme may also be involved in the regulation of these events.

3.2. Pathways leading to cPLA₂α activation that impact on LD formation.

Recent studies have suggested that cPLA₂α activation by phosphorylation is necessary for LD formation [20,46,52-54]. The relevant phosphorylation with regard to LD formation is the one that occurs at Ser⁵⁰⁵, catalyzed by different members of the mitogen-associated protein kinase (MAPK) family of enzymes [55]. Depending on cell type and stimulus, this phosphorylation is carried out by the extracellular-regulated kinases p42 and p48, p38, and/or SAPK/JNK [55]. This phosphorylation occurs much before the cells start making LDs in response to stimulation and its inhibition strongly blocks LD formation [20,46,52-54].

cPLA₂α phosphorylation at Ser⁵⁰⁵ in cells subjected to different stress conditions appears to be necessary and sufficient for LD formation even at Ca²⁺ levels similar to those found in unstimulated cells [46]. This is consistent with results showing that pathogens such as bacteria, fungi or virus, which are recognized by Toll-like receptors and activate MAPK signaling pathways and cPLA₂α in inflammatory cells in the absence of sustained intracellular Ca²⁺ elevations [29,71,72], are strong inducers of LD formation in these cells [15,64,73-75]. This LD induction is accompanied by the translocation of cPLA₂α to the LD surface, an event that may serve to modulate and/or amplify the inflammatory response, as it allows the enzyme to reach the AA-containing phospholipids on the LD surface [12,15]. This translocation is likely necessary as well to regulate the biogenesis of the organelle itself, as discussed in the previous section. Coincidentally, phosphorylation of cPLA₂α on Ser⁵⁰⁵ is also required for translocation of the enzyme to phagosomes in macrophages responding to phagocytic stimuli [56]. Since a tight association between LDs and phagosomes appears to exist in immunoinflammatory cells [64], it is possible that cPLA₂α plays similar regulatory

roles for both LD formation and phagosome maturation in cells involved in innate immunity and inflammation.

Although the addition of serum to serum-starved cells leads to the rapid activation of all three major MAPK family members, namely, p44/p42, p38, and JNK, only JNK activation is involved in cPLA₂α phosphorylation at Ser⁵⁰⁵ [52]. Moreover, serum-induced LD formation triggers the activation of ceramide kinase, leading to increased levels of ceramide 1-phosphate, which in turn regulates the phosphorylation activation of cPLA₂α [53]. Interestingly, down-regulation of ceramide kinase blunts not only cPLA₂α phosphorylation and LD formation but also JNK activation [20,53], suggesting that, with independence of any direct effect of ceramide 1-phosphate on cPLA₂α [76], the lipid may also affect other events that lie well upstream of the phospholipase.

In studies with human monocytes, it was found that not only JNK, but also p38 is required for the full phosphorylation activation of cPLA₂α and subsequent LD formation [54]. Inhibition of one of these kinases but not the other, reduced but not abolished cPLA₂α phosphorylation and LD formation, and simultaneous inhibition of both kinases was required for complete blockade of the responses [54]. Since both JNK and p38 regulate the phosphorylation of cPLA₂α at the same residue, these data suggest the participation of an intermediate kinase, activated by both JNK and p38, which would be the one that directly phosphorylates cPLA₂α at Ser⁵⁰⁵ and facilitates LD synthesis. An analogous mechanism for the phosphorylation activation of cPLA₂α by two distinct MAPK pathways has been reported in cardiomyocytes stimulated with ATP, where it was found that blockade of mitogen and stress-activated kinase-1, a kinase that is phosphorylated/activated by both p38 and p42/p44, resulted in inhibition

of cPLA₂α phosphorylation activation and of attendant cellular responses [77].

In some cellular systems, it has been reported that the regulatory effect of cPLA₂α on LD formation is not exerted directly, but rather occurs after formation of downstream metabolites, i.e. eicosanoids generated by oxygenation of the cPLA₂α product free AA [78]. However, when added exogenously, the free fatty acid is able to induce significant LD formation in cells in the presence of cyclooxygenase and lipoxygenase inhibitors [38,39,52,54]. Importantly, this process occurs in a cPLA₂α-dependent manner, because blockade of the enzyme strongly inhibits LD formation [52,54]. Moreover, free AA itself induces the phosphorylation activation of cPLA₂α [11,54], thereby promoting more AA mobilization. A remarkable positive loop of activation would therefore be established that results in optimal LD formation.

3.3. cPLA₂α role in LD formation in macrophages exposed to modified LDL

Circulating modified LDL, a major risk for the development of atherosclerosis, is taken up by macrophages and delivered to lysosomes, where part of its CE content is degraded by an acid lipase, and the resulting free cholesterol utilized for membrane synthesis. When the amount of free cholesterol is excessive it is re-acylated by ACAT and stored in cytoplasmic LDs. Cells use this energy-expensive mechanism to avoid lipotoxicity, which is a major cause of macrophage apoptosis and atherosclerosis progression [79,80].

It is noteworthy that the fatty acid composition of foam cells, containing primarily oleic acid, differs from that of LDLs, in which linoleic acid predominates [47]. This finding constitutes a strong indication that a significant part of the acyl-CoA

pool that is utilized to reacylate excess free cholesterol for LD storage must come from endogenous sources [47]. Studies aimed at delineating the intracellular sources of this fatty acyl-CoA in ox-LDL-treated macrophages came up with the finding that methyl arachidonoyl fluorophosphonate, a dual inhibitor of both cPLA₂ and iPLA₂ enzymes, but not bromoenol lactone, an iPLA₂ inhibitor [81], blocked CE synthesis, thus pointing to the involvement of a cPLA₂ form, most likely cPLA₂α [47]. Independent studies had shown that macrophage treatment with oxLDL does induce the activation of cPLA₂α and subsequent release of eicosanoids [82].

Two mechanisms have been proposed for the regulation of cPLA₂-mediated CE formation and subsequent LD formation in ox-LDL-treated macrophages. The first one is the activation of the *de novo* pathway for ceramide synthesis. Elevated intracellular levels of ceramide and its phosphorylated product ceramide 1-phosphate are known to induce cPLA₂α activation [76,83,84]. Murine macrophages increase their ceramide levels after exposure to ox-LDL without changes in sphingomyelin levels, suggesting activation of ceramide synthesis *de novo*, and inhibition of this pathway with fumonisin B1 significantly reduces CE synthesis [85,86].

The second route that may regulate the cPLA₂α-mediated CE formation in ox-LDL-treated macrophages is the availability of the oxidized fatty acid 13-hydroxyoctadecadienoic acid (13-HODE), formed by oxidation of linoleic acid, the major fatty acid in LDL. 13-HODE can be released from ox-LDL in atherosclerotic lesions via lipoprotein-associated PLA₂ (group VIIA PLA₂) [87]. 13-HODE has been shown to activate cPLA₂α by favoring translocation of the enzyme to the membrane, where its substrate resides [47,88]. This effect may be mediated by the anionic character of 13-HODE, which facilitates cPLA₂α interaction with membranes, as has been reported with other anionic lipids [55,89,90] or perhaps also because 13-HODE

incorporation into membranes might affect their physical properties, increasing the susceptibility of membrane phospholipids to cPLA₂α [88]. Other major components of ox-LDL such as 7-ketocholesterol or 25-hydroxycholesterol did not mimic the effects of 13-HODE [88].

3.4. cPLA₂α role in neutral lipid accumulation in liver

Studies on the regulation of LD synthesis and accumulation in the liver are of great pathophysiological interest, owing to the essential role of this organ in neutral lipid synthesis and accumulation, lipoprotein assembly and secretion and cholesterol biosynthesis. Abnormal LD formation in liver appears to be intimately linked with a number of pathologies, including steatosis, steatohepatitis, cirrhosis, and hepatitis C virus infection [91-93].

Studies using cPLA₂α^{-/-} mice have shown that this enzyme is required for TAG deposition in liver in animals fed a high-fat diet, thus suggesting that blockade of cPLA₂α protects from hepatic steatosis under these conditions [94]. TAG blood levels were found to be similar in both cPLA₂α^{+/+} and cPLA₂α^{-/-} mice; however, PGE₂ levels were strongly reduced in the cPLA₂α^{-/-} animals, both under normal and high-fat diet [94]. PGE₂ is known to induce TAG accumulation in liver, acting via hepatocyte surface receptors [78], and to suppress TAG-rich VLDL secretion, resulting in its accumulation inside the hepatocyte [95]. Thus cPLA₂α-mediated release of AA and its conversion into PGE₂ via COX-2 may constitute a straightforward pathway through which the phospholipase regulates *in vivo* TAG accumulation in liver cells [94].

The life cycle of hepatitis C virus (HCV) appears to be tightly related to hepatocyte LDs and VLDL secretion [96], hence, the PLA₂-regulated LD formation could be exploited as a possible therapeutic strategy to manage HCV infection [97,98].

HCV takes advantage of the host cell machinery leading to LD formation, including cPLA₂α [74]. In accord with this, inhibition of cPLA₂α with the selective inhibitor pyrrophenone results in dramatic decreases in both LD formation and HCV infectivity [74]. Interestingly a second cPLA₂ form, cPLA₂γ, also appears to be involved in HCV replication and assembly, and its down-regulation also results in decreased HCV infectivity [99]. This effect of cPLA₂γ is thought to occur via regulation of membranous web formation, an endoplasmic reticulum-derived structure with unique shape and curvature that is essential in HCV replication and assembly [100]. The finding that cPLA₂γ is an endoplasmic reticulum-associated, inducible enzyme in hepatocytes [101], could help to explain its up-regulation following HCV infection and its role in endoplasmic reticulum-derived membranous web formation.

4. Calcium-independent phospholipase A₂

Human calcium-independent phospholipase A₂s (iPLA₂) constitute a diverse group of enzymes, referred to as the group VI in the classification of the PLA₂ superfamily of enzymes (Table I). As all of the group VI iPLA₂ enzymes share a patatin domain, they are also referred to as patatin-like phospholipase domain-containing lipases (PNPLA), which is perhaps a more suitable denomination, inasmuch as more than a half of the enzymes of this group actually exhibit little PLA₂ activity [22].

PNPLA-1 to -5 are enzymes actively involved in the metabolism of LD and the development of adipose tissue. These include PNPLA-2 or adipose TAG lipase, also called desnutrin, and PNPLA-3 or adiponutrin. However, as these enzymes exhibit very low or no PLA₂ activity at all, they will not be further considered in this review. There are many recent excellent articles addressing different aspects of these enzymes and the interested reader is referred to them for details [102-106].

Group VIA PLA₂, or iPLA₂β, is the prototypic iPLA₂ enzyme. iPLA₂β does not show any clear substrate preference in *in vitro* assays, being able to hydrolyze at comparable rates all kinds of phospholipids regardless of their fatty acid composition [22,107]. This lack of substrate specificity fits well with the originally proposed function of the enzyme as a major regulator of phospholipid fatty acyl chain remodeling under resting conditions [108-110]. Interestingly, recent results have suggested that under activation conditions, iPLA₂β may show some selectivity for hydrolyzing PC molecules carrying palmitic acid at the sn-1 position [34]. The molecular determinants and physiological implications of this finding remain to be determined.

4.1. iPLA₂β role in LD formation

iPLA₂β has been proposed as a key enzyme for TAG synthesis prior to stress-induced LD formation in serum deprived CHO-K1 cells [46]. The enzyme provides phospholipid-derived free fatty acids for esterification into neutral lipids [46]. The presence of lipid-rich serum in the cell culture medium also induces LDs in these cells, but this time in an iPLA₂β-independent manner because there is an exogenous source free fatty acid [46,52]. This has led to the suggestion that LD formation from endogenous lipid sources upon starvation conditions is a cell mechanism to convert structural components into energy-rich molecules and store them into LD to boost the survival of the cells [20,46,51].

LD formation under stress conditions also involves participation of cPLA₂α (see preceding section), and this enzyme appears to act after iPLA₂β because both cPLA₂α activity and AA release depend on an active iPLA₂β [46] (Figure 2). These data would be in accord with findings that TAG synthesis, mediated by iPLA₂β, occurs prior to proper LD formation and, in turn, may suggest a regulatory role to iPLA₂β beyond that

of merely providing free fatty acids for TAG synthesis [46]. It is intriguing to speculate with possible mechanisms mediating cross-talk between iPLA₂β and cPLA₂α. A straightforward mechanism for this interplay could be one where products of iPLA₂β action on phospholipids regulate, directly or indirectly, cPLA₂α activation. For example, free fatty acids could directly activate cPLA₂α to induce LD formation in monocytes [54], and the activation of MAPK-derived signaling, including cPLA₂α phosphorylation, has been described to lay downstream of iPLA₂β activation under certain conditions [111]. Coordinate actions of both iPLA₂β and cPLA₂α in regulating cellular signaling leading to LD formation have also recently been suggested in macrophages treated with a snake venom PLA₂ [48].

4.2. iPLA₂γ role in LD formation

The other widely-studied member of the iPLA₂ family is the group VIB enzyme, iPLA₂γ. Its localization in peroxisomal and mitochondrial membranes suggests that this enzyme may be involved in the integration of lipid and energy metabolism [22]. A brief caloric restriction has been reported to induce phospholipid fatty acid turnover and TAG accumulation in murine myocardium as a mechanism to supply energy to cells [112]. iPLA₂γ overexpression in these cells increases both phospholipid fatty acid turnover and TAG accumulation after a caloric restriction [113]. Under glucose deprivation, lipids are incorporated by cells more efficiently as a mechanism to obtain energy. Because iPLA₂γ overexpression results in increased mitochondrial phospholipid turnover, these organelles appear morphological disrupted, resulting in functional abnormalities. As a consequence of this, fatty acids are not efficiently β-oxidized, which leads to their storage in cytoplasmic LDs to avoid lipotoxicity [113].

5. Secreted Phospholipase A₂S

To date, 11 sPLA₂S have been identified in mammals, classified into groups I, II, III, V, X and XII (Table I). These enzymes are characterized by a low molecular weight (13-18 KDa), the requirement of millimolar concentrations of Ca²⁺ to carry out their catalytic activity and the presence of multiple disulfide bonds in their structure [21,22]. Subtle differences exist regarding the substrate preference of these enzymes. Thus, some enzymes show preference for anionic phospholipids over PC (the group IIA enzyme), and vice versa (groups V and X). Regarding fatty acid specificity, the group V enzyme seems to prefer oleic acid and linoleic acid chains, group X shows some specificity for AA, and group III shows no specificity at all [21,22].

5.1. sPLA₂ role in atherosclerosis

Atherosclerosis is a multifactorial pathology that constitutes the main risk factor for cardiovascular disease. Atherosclerosis is characterized by the retention of macrophages in the artery wall, and their transformation into foam cells due to the intracellular accumulation of lipoprotein-derived neutral lipids, primarily CE, in the form of LDs [114].

sPLA₂S have been found in atherosclerotic lesions, probably originating from the monocytes/macrophages, and a role for these enzymes in the emergence and progression of the disease has been repeatedly proposed [115,116].

From a general point of view, sPLA₂ forms may modify native circulating lipoproteins through the hydrolysis of their phospholipids, thereby generating free fatty acids and lysophospholipids that change the size, electric charge, oxidation susceptibility and/or aggregation state of the native lipoprotein particles. These changes facilitate their internalization by macrophages, resulting in LD accumulation and foam

cell formation by different mechanisms depending on the affinity of sPLA₂ enzymes to the different substrates. *In vitro* studies have shown that among all sPLA₂s putatively involved in atherosclerosis progression, the group X enzyme is the most potent hydrolytic enzyme, followed by groups V, and III. Groups IIA, IIE and IIF exhibit low rates of hydrolysis of LDL particles [117]. Since PC species are the major phospholipid constituents of native LDL particles and the group X, V and III sPLA₂s rapidly and efficiently hydrolyze this phospholipid, native LDL particles are converted into more aggregated small-dense particles because of the reduction in their phospholipid content [50,117,118]. These small dense LDL particles present a potent pro-atherogenic potential due, in part, to a higher oxidation susceptibility and also to their exposure to proteoglycan-binding regions [119], increasing their subendothelial accumulation, uptake by macrophages, LD formation and foam cell accumulation.

On the other hand, the accumulation of large amounts of sPLA₂-derived fatty acids and lysophospholipids increases the negative electric charge of native LDL particles similar to when they become oxidized, and thus the particles acquire an ox-LDL-like phenotype that could constitute another potential mechanism for sPLA₂-mediated foam cell formation. However, this is a subject of much debate. While ox-LDL particles have been found to be internalized via scavenger receptors (CD36, SR-A) by macrophages [120,121], the involvement of such receptors in sPLA₂-modified LDL particle internalization is unclear [50,122]. These results, along with the different time-courses and localizations of internalized of sPLA₂-modified versus oxidized LDLs, suggest that the change in electric charge of LDL particles following sPLA₂ hydrolysis could not be of pathophysiological consequence for the accumulation of LDs in macrophages. Some studies have been carried out in the presence of albumin to remove fatty acids and lysophospholipids from the sPLA₂-modified LDL [50,123,124]. This

strategy reduced the negative charge of the particles but did not affect LDLs accumulation [123,124]. Since albumin is abundant in atherosclerotic foci, the electric charge of the LDL particles may not change much after sPLA₂-catalyzed phospholipid hydrolysis under pathophysiologically-relevant settings, which could explain the differences in compartmentalization and time-dependent accumulation of neutral lipids by macrophages compared with cells exposed to the strongly negatively charged ox-LDL [120].

Group IIA sPLA₂ constitutes a special case among sPLA₂s because it only hydrolyzes a small amount of phospholipids within LDLs due to its preference for phospholipids containing anionic head groups [21,22]. Group IIA sPLA₂-overexpressing mice show minimal changes in the phospholipid composition of circulating LDLs compared with their wild-type littermates after 8 weeks on a high-fat diet [125]. Despite this reduced potential to hydrolyze LDLs compared to other sPLA₂s [123], group IIA sPLA₂ has also been strongly related with atherosclerosis emergence and progression [126] due to the involvement of this enzyme in facilitating the migration of LDL particles to the subendothelium [117,123]. Group IIA sPLA₂ is bound to intima proteoglycans [127], and promotes the interaction of ApoB-containing LDL with proteoglycans [128], thereby increasing the probability of the particle to undergo oxidation and to accumulate in the form of intima-associated 'extracellular LD' [129].

sPLA₂-induced hydrolysis of lipoprotein phospholipids may lead to the release of significant amounts of AA [117,118,123]. Among the many biological activities of AA, there is its ability to potently induce LD formation in human monocytes [54], suggesting a proatherogenic role for AA, which may manifest even before monocyte extravasation and differentiation into macrophages has occurred [54,130].

It is well known that, contrary to LDL, HDL plays a protective role in

atherosclerosis, contributing to the reverse efflux of CE from foam cells to their degradation in the liver [131]. Groups V and X sPLA₂s can hydrolyze phospholipids in either HDL or LDL particles at similar rates [117]. Thus the pro-atherogenic role of some sPLA₂s with regard to LD formation in macrophages could also be explained by the decreased reduction of LD levels that macrophages experience when exposed to sPLA₂-modified HDL instead of native HDL [132]. The cholesterol efflux from macrophages to HDL is mediated by the expression of scavenger receptor B type I (SR-BI) on the surface of macrophages, and its up-regulation induces an increase in the rate of CE efflux, resulting in the reduction of LD formation [133]. The presence of phospholipids in HDL acceptor particles plays a key role in their CE efflux properties, because the more enriched in phospholipid the HDL particle, the better the interaction with the SR-BI receptor and hence, the higher the CE efflux [132,133]. Thus, a reduction in HDL phospholipid content due to sPLA₂ hydrolysis may explain the decrease in CE efflux from macrophages.

Because of the wealth of data suggesting a prominent role for sPLA₂s in the development and progression of atherosclerosis, pharmacological inhibition of these enzymes has been contemplated as a possible therapeutic approach to treating cardiovascular disease [116]. Unfortunately, recent trials testing the effect of varespladib, an inhibitor of group IIA sPLA₂ which most likely also inhibits groups V and X, have provided discouraging results. sPLA₂ inhibition with this drug did not reduce the risk of recurrent recurrent cardiovascular events in patients with acute coronary syndrome and actually increased the risk of myocardial infarction [134,135]. Clearly, further studies are needed to establish whether targeting the production of bioactive lipids via sPLA₂ inhibition will have a clinical benefit.

5.2. Other sPLA₂ roles

A striking feature of tumor proliferating cells is their lipogenic phenotype, to provide building blocks for making new membrane or to supply energy for growth [136,137]. These cells also synthesize significant amounts of LDs as a survival mechanism under starvation conditions [51]. Some sPLA₂ enzymes have been related to cancer development by different mechanisms, including the release of AA and the synthesis of eicosanoids, and the stimulation of LD synthesis [138].

Incubation of MDA-MB-231 human breast cancer cells with group X sPLA₂ results in increased LD formation by a mechanism that fully depends on the activity of the enzyme [51]. These cells also show up-regulation of their β -oxidation related genes and repression of the *de novo* lipogenesis genes [51]. This is in accordance with other studies showing that the sole overexpression of group X sPLA₂ results in reduced TAG levels in cultured pre-adipocyte cells, and decreased transcription of genes encoding for lipogenic proteins such as SREBP-1c, fatty acid synthase or PPAR γ [139]. Inhibition of fatty acid β -oxidation with etomoxir reduces LD formation in response to group X sPLA₂, highlighting the seemingly odd circumstance that anabolic –neutral lipid formation and storage in LD– and catabolic – β -oxidation of fatty acids– processes take place simultaneously. Thus, fatty acids released by the action of group X sPLA₂ on membranes can follow two opposite routes, and the proposal has been made that one route may serve to support the other, e.g. fatty acid β -oxidation products such as ATP or NADPH could be needed to support LD biogenesis [20,51].

The group XII of the PLA₂ family consists of two members, XIIA and XIIB. Both PLA₂s have the same sequence except for the fact that the active site His in group XIIA is replaced with Leu in Group XIIB, which makes the later catalytically inactive [21,22]. In spite of this, group XIIB sPLA₂, which is quite abundant in hepatocytes,

appears to play a prominent role in regulating LD size and number in these cells [140,141]. By acting downstream of the transcription factor hepatocyte nuclear factor-4 α (HNF-4 α), group XIIB sPLA₂ regulates VLDL secretion from the liver to the bloodstream. Down-regulation of the enzyme results in reduced VLDL secretion and the accumulation of TAG in the form of LDs into hepatocytes, leading to a fatty liver phenotype as well as the concomitant decrease in circulating HDL, LDL and TAG levels. In the group XIIB sPLA₂^{-/-} mice, the genes encoding for fatty acid synthase and stearoyl-CoA desaturase-1 appear down-regulated, perhaps as a response to the excessive accumulation of LDs in the hepatocytes of these mice [141].

6. Roles of other Phospholipases A₂

PAF acetyl hydrolases are a group of PLA₂s which hydrolyze acetate from the sn-2 position of PAF, releasing acetic acid and 1-O-alkyl-PC (i.e. lyso-PAF). To date, four of these enzymes have been described, and one of them, group VIIA PLA₂, also known as Ca²⁺-independent secreted PAF acetyl hydrolase, or lipoprotein-associated PLA₂ (Lp-PLA₂), has been related with foam cell formation [142]. In addition to PAF, this enzyme also hydrolyzes phospholipids containing a short-chain oxidized fatty acid at the sn-2 position [21,22].

In some studies, an anti-atherogenic function for Lp-PLA₂ has been assigned through the reduction of early foam cell formation in blood vessels. Lp-PLA₂ overexpression protects HDL and LDL from oxidation, on one hand converting LDL to a less proatherogenic particle and, on the other hand, preventing the reduction of the HDL-mediated CE reverse efflux transport from macrophages [132]. This results in the reduction of foam cell formation and atherosclerosis injury in *in vivo* models [143].

Moreover, foam cell formation in RAW264.7 macrophages is also decreased when the cells are incubated with ox-LDL particles that contain Lp-PLA₂ activity. Inhibition of the Lp-PLA₂ activity associated to the particles leads to increased foam cell formation [144].

On a different view, the products of Lp-PLA₂ action on lipoprotein phospholipids, lysoPC and oxidized fatty acids, are both well established proinflammatory mediators. Accordingly, and despite the protective role that this enzyme appears to exert on foam cell formation, a predominant pro-atherogenic role has been assigned to this enzyme owing to its ability to generate pro-inflammatory substances which may contribute to atherosclerosis progression by several mechanisms [142,145]. The presence of this enzyme in plasma has been deemed as a marker of coronary risk [146]. The pharmaceutical industry has developed a number of reversible inhibitors for this enzyme and one of them, darapladib, has been tested in clinical trials in humans with discouraging results [147].

Group XV PLA₂ or lysosomal PLA₂ hydrolyzes PC and PE substrates under acidic conditions in a Ca²⁺-independent manner [21,22,148]. This enzyme is highly expressed in alveolar macrophages and contributes to the metabolism of the pulmonary surfactant [148]. Macrophages from mice lacking group XV PLA₂ present a massive accumulation of phospholipids in the form of lamellar body inclusions, indicative of cellular phospholipidosis [148]. Phospholipidosis is related with a foam cell phenotype similar to that of macrophages challenged with ox-LDL. According with the protective role of group XV PLA₂ in foam cell formation, mice lacking this enzyme develop more severe lesions than their wild type littermates in a model of atherosclerosis [148].

7. Concluding remarks

The interest for LDs is rapidly increasing but still little is known about the mechanisms governing their formation. The studies discussed in this article regarding the involvement of PLA₂s constitute a starting point for a detailed understanding of molecular mechanisms and participating pathways. Clearly, this is a very complex issue involving multiple enzymes, and there is still much to be learned about the interplay between some of the participant PLA₂ enzymes and the regulatory processes involved.

Acknowledgements

Work in our laboratories was supported by the Spanish Ministry of Science and Innovation (Grants BFU2010-18826 and SAF2010-18831), and the Education Department of the Autonomous Government of Castile and Leon (Grant CSI007U13). C. G. was supported by a predoctoral fellowship from the University of Valladolid. CIBERDEM is an initiative of Instituto de Salud Carlos III.

References

- [1] W. Fei, L. Zhong, M.T. Ta, G. Shui, M.R. Wenk, H. Yang, The size and phospholipid composition of lipid droplets can influence their proteome, *Biochem. Biophys. Res. Commun.* 415 (2011) 455-462.
- [2] K. Grillitsch, M. Connerth, H. Kofeler, T.N. Arrey, B. Rietschel, B. Wagner, M. Karas, G. Daum, Lipid particles/droplets of the yeast *Saccharomyces cerevisiae* revisited: lipidome meets proteome, *Biochim. Biophys. Acta* 1811 (2011) 1165-1176.
- [3] K. Tauchi-Sato, S. Ozeki, T. Houjou, R. Taguchi, T. Fujimoto, The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition, *J. Biol. Chem.* 277 (2002) 44507-44512.
- [4] A. Penno, G. Hackenbroich, C. Thiele, Phospholipids and lipid droplets, *Biochim. Biophys. Acta* 1831 (2013) 589-594.
- [5] A.R. Kimmel, D.L. Brasaemle, M. McAndrews-Hill, C. Sztalryd, C. Londos, Adoption of PERILIPIN as a unifying nomenclature for the mammalian PAT-family of intracellular lipid storage droplet proteins, *J. Lipid Res.* 51 (2010) 468-471.
- [6] A. Lass, R. Zimmermann, M. Oberer, R. Zechner, Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores, *Prog. Lipid Res.* 50 (2011) 14-27.
- [7] J. L. Cantley, T. Yoshimura, J. P. Camporez, D. Zhang, F. R. Jornayvaz, N. Kumashiro, F. Guebre-Egziabher, M. J. Jurczak, M. Kahn, B. A. Guigni, J. Serr, J. Hankin, R. C. Murphy, G. W. Cline, S. Bhanot, V. P. Manchem, J. M. Brown, V. T. Samuel, G. I. Shulman GI, CGI-58 knockdown sequesters diacylglycerols in lipid

droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance, *Proc. Natl. Acad. Sci. U.S.A.* 110 (2013) 1869-1874.

[8] N. Kraemer, Y. Guo, F. Wilfling, M. Hilger, S. Lingrell, K. Heger, H.W. Newman, M. Schmidt-Supprian, D.E. Vance, M. Mann, R.V. Farese, Jr., T.C. Walther, Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase, *Cell Metab.* 14 (2011) 504-515.

[9] M. Valdearcos, E. Esquinas, C. Meana, L. Gil-de-Gomez, C. Guijas, J. Balsinde, M.A. Balboa, Subcellular localization and role of lipin-1 in human macrophages, *J. Immunol.* 186 (2011) 6004-6013.

[10] H. Sembongi, M. Miranda, G.S. Han, S. Fakas, N. Grimsey, J. Vendrell, G.M. Carman, S. Siniouoglou, Distinct roles of the phosphatidate phosphatases lipin 1 and 2 during adipogenesis and lipid droplet biogenesis in 3T3-L1 cells, *J. Biol. Chem.* 288 (2013) 34502-34513.

[11] R.E. Wooten, M.C. Willingham, L.W. Daniel, C.C. Leslie, L.C. Rogers, S. Sergeant, J.T. O'Flaherty, Novel translocation responses of cytosolic phospholipase A₂α fluorescent proteins, *Biochim. Biophys. Acta* 1783 (2008) 1544-1550.

[12] A. Khatchadourian, S.D. Bourque, V.R. Richard, V.I. Titorenko, D. Maysinger, Dynamics and regulation of lipid droplet formation in lipopolysaccharide (LPS)-stimulated microglia, *Biochim. Biophys. Acta* 1821 (2012) 607-617.

[13] D.J. Murphy, The biogenesis and functions of lipid bodies in animals, plants and microorganisms, *Prog. Lipid Res.* 40 (2001) 325-438.

[14] A. Pol, S.P. Gross, R.G. Parton, Biogenesis of the multifunctional lipid droplet: Lipids, proteins, and sites, *J. Cell Biol.* 204 (2014) 635-646.

- [15] P.T. Bozza, K.G. Magalhaes, P.F. Weller, Leukocyte lipid bodies - Biogenesis and functions in inflammation, *Biochim. Biophys. Acta* 1791 (2009) 540-551.
- [16] Y. Fujimoto, J. Onoduka, K.J. Homma, S. Yamaguchi, M. Mori, Y. Higashi, M. Makita, T. Kinoshita, J. Noda, H. Itabe, T. Takanoa, Long-chain fatty acids induce lipid droplet formation in a cultured human hepatocyte in a manner dependent of Acyl-CoA synthetase, *Biol. Pharm. Bull.* 29 (2006) 2174-2180.
- [17] A. Herms, M. Bosch, N. Ariotti, B.J. Reddy, A. Fajardo, A. Fernandez-Vidal, A. Alvarez-Guaita, M.A. Fernandez-Rojo, C. Rentero, F. Tebar, C. Enrich, M.I. Geli, R.G. Parton, S.P. Gross, A. Pol, Cell-to-cell heterogeneity in lipid droplets suggests a mechanism to reduce lipotoxicity, *Curr. Biol.* 23 (2013) 1489-1496.
- [18] A.R. Thiam, R.V. Farese, Jr., T.C. Walther, The biophysics and cell biology of lipid droplets, *Nat. Rev. Mol. Cell Biol.* 14 (2013) 775-786.
- [19] Y. Ohsaki, M. Suzuki, T. Fujimoto, Open questions in lipid droplet biology, *Chem. Biol.* 21 (2014) 86-96.
- [20] A.G. Cabodevilla, L. Sanchez-Caballero, E. Nintou, V.G. Boiadjieva, F. Picatoste, A. Gubern, E. Claro, Cell survival during complete nutrient deprivation depends on lipid droplet-fueled beta-oxidation of fatty acids, *J. Biol. Chem.* 288 (2013) 27777-27788.
- [21] E.A. Dennis, J. Cao, Y. H. Hsu, V. Magrioti, G. Kokotos, Phospholipase A₂ enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention, *Chem. Rev.* 111 (2011) 6130–6185.

- [22] M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, K. Yamamoto, Recent progress in phospholipase A₂ research: from cells to animals to humans, *Prog. Lipid Res.* 50 (2011) 152-192.
- [23] J. Balsinde, M. A. Balboa, P. A. Insel, and E. A. Dennis. Regulation and inhibition of phospholipase A₂. *Annu. Rev. Pharmacol. Toxicol.* 39 (1999) 175-89
- [24] J. Balsinde, M. V. Winstead, and E. A. Dennis. Phospholipase A₂ regulation of arachidonic acid mobilization. *FEBS Lett.* 531 (2002) 2-6
- [25] C. C. Leslie. Regulation of arachidonic acid availability for eicosanoid production. *Biochem Cell Biol.* 82 (2004) 1-17
- [26] M. Ghosh, D.E. Tucker, S.A. Burchett, C.C. Leslie, Properties of the Group IV phospholipase A₂ family, *Prog. Lipid Res.* 45 (2006) 487-510.
- [27] W.K. Han, A. Sapirstein, C.C. Hung, A. Alessandrini, J.V. Bonventre, Cross-talk between cytosolic phospholipase A₂α (cPLA₂α) and secretory phospholipase A₂ (sPLA₂) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA₂ regulates cPLA₂α activity that is responsible for arachidonic acid release, *J. Biol. Chem.* 278 (2003) 24153-24163.
- [28] E. Kikawada, J.V. Bonventre, J.P. Arm, Group V secretory PLA₂ regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA₂α activation, *Blood* 110 (2007) 561-567.
- [29] V. Ruipérez, A.M. Astudillo, M.A. Balboa, J. Balsinde, Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A₂s, *J. Immunol.* 182 (2009) 3877-3883.

- [30] N.M. Muñoz, Y.J. Kim, A.Y. Meliton, K.P. Kim, S.K. Han, E. Boetticher, E. O'Leary, S. Myou, X. Zhu, J.V. Bonventre, A.R. Leff, W. Cho, Human group V phospholipase A₂ induces group IVA phospholipase A₂-independent cysteinyl leukotriene synthesis in human eosinophils, *J. Biol. Chem.* 278 (2003) 38813-38820.
- [31] J. Balsinde, M.A. Balboa, Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A₂ in activated cells, *Cell. Signal.* 17 (2005) 1052-1062.
- [32] R. Pérez, R. Melero, M.A. Balboa, J. Balsinde, Role of group VIA calcium-independent phospholipase A₂ in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide, *J. Biol. Chem.* 279 (2004) 40385-40391.
- [33] R. Pérez, M. A. Balboa, J. Balsinde, Involvement of group VIA calcium-independent phospholipase A₂ in macrophage engulfment of hydrogen peroxide-treated U937 cells. *J. Immunol.* 176 (2006) 2555-2561.
- [34] L. Gil-de-Gómez, A.M. Astudillo, C. Guijas, V. Magrioti, G. Kokotos, M.A. Balboa, J. Balsinde, Cytosolic group IVA and calcium-independent group VIA phospholipase A₂s act on distinct phospholipid pools in zymosan-stimulated mouse peritoneal macrophages, *J. Immunol.* 192 (2014) 752-762.
- [35] C.C. Leslie, T.A. Gangelhoff, M.H. Gelb, Localization and function of cytosolic phospholipase A₂ α at the Golgi, *Biochimie* 92 (2010) 620-626.
- [36] A. M. Astudillo, D. Balgoma, M. A. Balboa, J. Balsinde, Dynamics of arachidonic acid mobilization by inflammatory cells, *Biochim. Biophys. Acta* 1821 (2012) 249-256.

- [37] X. Lei, S.E. Barbour, S. Ramanadham, Group VIA Ca^{2+} -independent phospholipase A_2 (iPLA $_2\beta$) and its role in beta-cell programmed cell death, *Biochimie* 92 (2010) 627-637.
- [38] P.F. Weller, S.W. Ryeom, S.T. Picard, S.J. Ackerman, A.M. Dvorak, Cytoplasmic lipid bodies of neutrophils: formation induced by cis-unsaturated fatty acids and mediated by protein kinase C, *J. Cell Biol.* 113 (1991) 137-146.
- [39] A. Dichlberger, S. Schlager, J. Lappalainen, R. Kakela, K. Hattula, S.J. Butcher, W.J. Schneider, P.T. Kovanen, Lipid body formation during maturation of human mast cells, *J. Lipid Res.* 52 (2011) 2198-2208.
- [40] A. M. Astudillo, G. Pérez-Chacón, D. Balgoma, L. Gil-de-Gómez, V. Ruipérez, C. Guijas, M. A. Balboa, J. Balsinde. Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells. *Biochim. Biophys. Acta* 1811 (2011) 97-103.
- [41] W. Yu, P.T. Bozza, D.M. Tzizik, J.P. Gray, J. Cassara, A.M. Dvorak, P.F. Weller, Co-compartmentalization of MAP kinases and cytosolic phospholipase A_2 at cytoplasmic arachidonate-rich lipid bodies, *Am. J. Pathol.* 152 (1998) 759-769.
- [42] P.T. Bozza, J.P. Viola, Lipid droplets in inflammation and cancer, *Prostag. Leukot. Essent. Fatty Acids* 82 (2010) 243-250.
- [43] M. A. Balboa, J. Balsinde, and E. A. Dennis. 1998. Involvement of phosphatidate phosphohydrolase in arachidonic acid mobilization in human amnionic WISH cells. *J. Biol. Chem.* 273: 7684-7690

- [44] C. A. Johnson, M. A. Balboa, J. Balsinde, E. A. Dennis, Regulation of cyclooxygenase-2 expression by phosphatidate phosphohydrolase in human amnionic WISH cells, *J. Biol. Chem.* 274 (1999) 27689–27693.
- [45] A. Grkovich, A. Armando, O. Quehenberger, E. A. Dennis, TLR-4 mediated group IVA phospholipase A₂ activation is phosphatidic acid phosphohydrolase 1 and protein kinase C dependent. *Biochim. Biophys. Acta* 1791 (2009) 975-982.
- [46] A. Gubern, M. Barceló-Torns, J. Casas, D. Barneda, R. Masgrau, F. Picatoste, J. Balsinde, M.A. Balboa, E. Claro, Lipid droplet biogenesis induced by stress involves triacylglycerol synthesis that depends on group VIA phospholipase A₂, *J. Biol. Chem.* 284 (2009) 5697-5708.
- [47] S. Akiba, Y. Yoneda, S. Ohno, M. Nemoto, T. Sato, Oxidized LDL activates phospholipase A₂ to supply fatty acids required for cholesterol esterification, *J. Lipid Res.* 44 (2003) 1676-1685.
- [48] E. Leiguez, J.P. Zuliani, A.M. Cianciarullo, C.M. Fernandes, J.M. Gutierrez, C. Teixeira, A group IIA-secreted phospholipase A₂ from snake venom induces lipid body formation in macrophages: the roles of intracellular phospholipases A₂ and distinct signaling pathways, *J. Leukoc. Biol.* 90 (2011) 155-166.
- [49] K. Hanasaki, K. Yamada, S. Yamamoto, Y. Ishimoto, A. Saiga, T. Ono, M. Ikeda, M. Notoya, S. Kamitani, H. Arita, Potent modification of low density lipoprotein by group X secretory phospholipase A₂ is linked to macrophage foam cell formation, *J. Biol. Chem.* 277 (2002) 29116-29124.
- [50] B.B. Boyanovsky, D.R. van der Westhuyzen, N.R. Webb, Group V secretory phospholipase A₂-modified low density lipoprotein promotes foam cell formation by a

SR-A- and CD36-independent process that involves cellular proteoglycans, *J. Biol. Chem.* 280 (2005) 32746-32752.

[51] A. Pucer, V. Brglez, C. Payre, J. Pungercar, G. Lambeau, T. Petan, Group X secreted phospholipase A₂ induces lipid droplet formation and prolongs breast cancer cell survival, *Mol. Cancer* 12 (2013) 111.

[52] A. Gubern, J. Casas, M. Barceló-Torns, D. Barneda, X. de la Rosa, R. Masgrau, F. Picatoste, J. Balsinde, M.A. Balboa, E. Claro, Group IVA phospholipase A₂ is necessary for the biogenesis of lipid droplets, *J. Biol. Chem.* 283 (2008) 27369-27382.

[53] A. Gubern, M. Barceló-Torns, D. Barneda, J.M. López, R. Masgrau, F. Picatoste, C.E. Chalfant, J. Balsinde, M.A. Balboa, E. Claro, JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A₂, *J. Biol. Chem.* 284 (2009) 32359-32369.

[54] C. Guijas, G. Perez-Chacón, A.M. Astudillo, J.M. Rubio, L. Gil-de-Gómez, M.A. Balboa, J. Balsinde, Simultaneous activation of p38 and JNK by arachidonic acid stimulates the cytosolic phospholipase A₂-dependent synthesis of lipid droplets in human monocytes, *J. Lipid Res.* 53 (2012) 2343-2354.

[55] G. Pérez-Chacón, A.M. Astudillo, D. Balmoma, M.A. Balboa, J. Balsinde, Control of free arachidonic acid levels by phospholipases A₂ and lysophospholipid acyltransferases, *Biochim. Biophys. Acta* 1791 (2009) 1103-1113.

[56] J. Casas, C. Meana, E. Esquinas, M. Valdearcos, J. Pindado, J. Balsinde, M.A. Balboa, Requirement of JNK-mediated phosphorylation for translocation of group IVA phospholipase A₂ to phagosomes in human macrophages, *J. Immunol.* 183 (2009) 2767-2774.

- [57] T.A. Lagace, N.D. Ridgway, The role of phospholipids in the biological activity and structure of the endoplasmic reticulum, *Biochim. Biophys. Acta* 1833 (2013) 2499-2510.
- [58] F. Wilfling, J.T. Haas, T.C. Walther, R.V. Jr, Lipid droplet biogenesis, *Curr. Opin. Cell Biol.* 29 (2014) 39-45.
- [59] R.A. Coleman, D.P. Lee, Enzymes of triacylglycerol synthesis and their regulation, *Prog. Lipid Res.* 43 (2004) 134-176.
- [60] H. Khandelia, L. Duelund, K.I. Pakkanen, J.H. Ipsen, Triglyceride blisters in lipid bilayers: implications for lipid droplet biogenesis and the mobile lipid signal in cancer cell membranes, *PLoS One* 5 (2010) e12811.
- [61] W.J. Brown, K. Chambers, A. Doody, Phospholipase A₂ (PLA₂) enzymes in membrane trafficking: mediators of membrane shape and function, *Traffic* 4 (2003) 214-221.
- [62] E. San Pietro, M. Capestrano, E.V. Polishchuk, A. DiPentima, A. Trucco, P. Zizza, S. Mariggio, T. Pulvirenti, M. Sallese, S. Tete, A.A. Mironov, C.C. Leslie, D. Corda, A. Luini, R.S. Polishchuk, Group IV phospholipase A₂ α controls the formation of inter-cisternal continuities involved in intra-Golgi transport, *PLoS Biol.* 7 (2009) e1000194.
- [63] K.D. Ha, B.A. Clarke, W.J. Brown, Regulation of the Golgi complex by phospholipid remodeling enzymes, *Biochim. Biophys. Acta* 1821 (2012) 1078-1088.
- [64] R.C. Melo, A.M. Dvorak, Lipid body-phagosome interaction in macrophages during infectious diseases: host defense or pathogen survival strategy?, *PLoS Pathog.* 8 (2012) e1002729.

- [65] N. Fuller, R.P. Rand, The influence of lysolipids on the spontaneous curvature and bending elasticity of phospholipid membranes, *Biophys. J.* 81 (2001) 243-254.
- [66] J. Zanghellini, F. Wodlei, H.H. von Grunberg, Phospholipid demixing and the birth of a lipid droplet, *J. Theor. Biol.* 264 (2010) 952-961.
- [67] C. Moessinger, L. Kuerschner, J. Spandl, A. Shevchenko, C. Thiele, Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine, *J. Biol. Chem.* 286 (2011) 21330-21339.
- [68] E.E. Kooijman, V. Chupin, N.L. Fuller, M.M. Kozlov, B. de Kruijff, K.N. Burger, P.R. Rand, Spontaneous curvature of phosphatidic acid and lysophosphatidic acid, *Biochemistry* 44 (2005) 2097-2102.
- [69] D. Marchesan, M. Rutberg, L. Andersson, L. Asp, T. Larsson, J. Boren, B.R. Johansson, S.O. Olofsson, A phospholipase D-dependent process forms lipid droplets containing caveolin, adipocyte differentiation-related protein, and vimentin in a cell-free system, *J. Biol. Chem.* 278 (2003) 27293-27300.
- [70] L. Andersson, P. Bostrom, J. Ericson, M. Rutberg, B. Magnusson, D. Marchesan, M. Ruiz, L. Asp, P. Huang, M.A. Frohman, J. Boren, S.O. Olofsson, PLD1 and ERK2 regulate cytosolic lipid droplet formation, *J. Cell Sci.* 119 (2006) 2246-2257.
- [71] J. Balsinde, M. A. Balboa, W.H. Li, J. Llopis, E. A. Dennis, Cellular regulation of cytosolic group IV phospholipase A₂ by phosphatidylinositol bisphosphate levels, *J. Immunol.* 164 (2000) 5398-5402.
- [72] M. A. Gijón, D. M. Spencer, A. R. Siddiqi, J. V. Bonventre, C. C. Leslie CC. Cytosolic phospholipase A₂ is required for macrophage arachidonic acid release by

agonists that do and do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A₂ regulation. *J. Biol. Chem.* 275 (2000) 20146-20156.

[73] K.R. Feingold, M.R. Kazemi, A.L. Magra, C.M. McDonald, L.G. Chui, J.K. Shigenaga, S.M. Patzek, Z.W. Chan, C. Londos, C. Grunfeld, ADRP/ADFP and Mal1 expression are increased in macrophages treated with TLR agonists, *Atherosclerosis* 209 (2010) 81-88.

[74] N. Menzel, W. Fischl, K. Hueging, D. Bankwitz, A. Frentzen, S. Haid, J. Gentzsch, L. Kaderali, R. Bartenschlager, T. Pietschmann, MAP-kinase regulated cytosolic phospholipase A₂ activity is essential for production of infectious hepatitis C virus particles, *PLoS Pathog.* 8 (2012) e1002829.

[75] Y.L. Huang, J. Morales-Rosado, J. Ray, T.G. Myers, T. Kho, M. Lu, R.S. Munford, Toll-like receptor agonists promote prolonged triglyceride storage in macrophages, *J. Biol. Chem.* 289 (2014) 3001-3012.

[76] R.V. Stahelin, P. Subramanian, M. Vora, W. Cho, C.E. Chalfant, Ceramide-1-phosphate binds group IVA cytosolic phospholipase A₂ via a novel site in the C2 domain, *J. Biol. Chem.* 282 (2007) 20467-20474.

[77] F. Aimond, J.M. Rauzier, C. Bony, G. Vassort, Simultaneous activation of p38 MAPK and p42/44 MAPK by ATP stimulates the K⁺ current ITREK in cardiomyocytes, *J. Biol. Chem.* 275 (2000) 39110-39116.

[78] N. Enomoto, K. Ikejima, S. Yamashina, A. Enomoto, T. Nishiura, T. Nishimura, D.A. Brenner, P. Schemmer, B.U. Bradford, C.A. Rivera, Z. Zhong, R.G. Thurman,

Kupffer cell-derived prostaglandin E₂ is involved in alcohol-induced fat accumulation in rat liver, *Am. J. Physiol.* 279G (2000) 100-106.

[79] I. Tabas, Cholesterol and phospholipid metabolism in macrophages, *Biochim. Biophys. Acta* 1529 (2000) 164-174.

[80] B. Feng, P.M. Yao, Y. Li, C.M. Devlin, D. Zhang, H.P. Harding, M. Sweeney, J.X. Rong, G. Kuriakose, E.A. Fisher, A.R. Marks, D. Ron, I. Tabas, The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages, *Nat. Cell Biol.* 5 (2003) 781-792.

[81] J. Balsinde, and E. A. Dennis. Distinct roles in signal transduction for each of the phospholipase A₂ enzymes present in P388D₁ macrophages. *J. Biol. Chem.* 271 (1996) 6758-6765.

[82] S.R. Panini, L. Yang, A.E. Rusiñol, M.S. Sinensky, J.V. Bonventre, C.C. Leslie, Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized LDL/oxysterol, *J. Lipid Res.* 42 (2001) 1678-1686.

[83] N.F. Lamour, P. Subramanian, D.S. Wijesinghe, R.V. Stahelin, J.V. Bonventre, C.E. Chalfant, Ceramide 1-phosphate is required for the translocation of group IVA cytosolic phospholipase A₂ and prostaglandin synthesis, *J. Biol. Chem.* 284 (2009) 26897-26907.

[84] A. Huwiler, B. Johansen, A. Skarstad, J. Pfeilschifter, Ceramide binds to the CaLB domain of cytosolic phospholipase A₂ and facilitates its membrane docking and arachidonic acid release, *FASEB J.* 15 (2001) 7-9.

[85] K. Kitatani, M. Nemoto, S. Akiba, T. Sato, Stimulation by de novo-synthesized ceramide of phospholipase A(2)-dependent cholesterol esterification promoted by the

uptake of oxidized low-density lipoprotein in macrophages, *Cell. Signal.* 14 (2002) 695-701.

[86] L.M. Halasiddappa, H. Koefeler, A.H. Futerman, A. Hermetter, Oxidized phospholipids induce ceramide accumulation in RAW 264.7 macrophages: role of ceramide synthases, *PLoS One* 8 (2013) e70002.

[87] V.A. Tyurin, N. Yanamala, Y.Y. Tyurina, J. Klein-Seetharaman, C.H. Macphee, V.E. Kagan, Specificity of lipoprotein-associated phospholipase A₂ toward oxidized phosphatidylserines: liquid chromatography-electrospray ionization mass spectrometry characterization of products and computer modeling of interactions, *Biochemistry* 51 (2012) 9736-9750.

[88] S. Akiba, H. Ii, Y. Yoneda, T. Sato, Translocation of phospholipase A₂ to membranes by oxidized LDL and hydroxyoctadecadienoic acid to contribute to cholesteryl ester formation, *Biochim. Biophys. Acta* 1686 (2004) 77-84.

[89] J. Casas, M.A. Gijón, A.G. Vigo, M.S. Crespo, J. Balsinde, M.A. Balboa, Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A₂ to perinuclear membranes and decreases its calcium requirement for translocation in live cells, *Mol. Biol. Cell* 17 (2006) 155-162.

[90] P. Subramanian, M. Vora, L.B. Gentile, R.V. Stahelin, C.E. Chalfant, Anionic lipids activate group IVA cytosolic phospholipase A₂ via distinct and separate mechanisms, *J. Lipid Res.* 48 (2007) 2701-2708.

[91] J. McLauchlan, Lipid droplets and hepatitis C virus infection, *Biochim. Biophys. Acta*, 1791 (2009) 552-559.

- [92] Z. Yao, H. Zhou, D. Figeys, Y. Wang, M. Sundaram, Microsome-associated luminal lipid droplets in the regulation of lipoprotein secretion, *Curr. Opin. Lipidol.* 24 (2013) 160-170.
- [93] N. Sahini, J. Borlak, Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes, *Prog. Lipid Res.* 54 (2014) 86-112.
- [94] H. Ii, N. Yokoyama, S. Yoshida, K. Tsutsumi, S. Hatakeyama, T. Sato, K. Ishihara, S. Akiba, Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A₂-knockout mice, *PLoS One* 4 (2009) e8089.
- [95] S. Pérez, P. Aspichueta, B. Ochoa, Y. Chico, The 2-series prostaglandins suppress VLDL secretion in an inflammatory condition-dependent manner in primary rat hepatocytes, *Biochim. Biophys. Acta*, 1761 (2006) 160-171.
- [96] Y. Miyanari, K. Atsuzawa, N. Usuda, K. Watashi, T. Hishiki, M. Zayas, R. Bartenschlager, T. Wakita, M. Hijikata, K. Shimotohno, The lipid droplet is an important organelle for hepatitis C virus production, *Nat. Cell Biol.* 9 (2007) 1089-1097.
- [97] G.H. Syed, A. Siddiqui, Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus, *Hepatology* 54 (2011) 1936-1946.
- [98] D.J. Felmlee, T.F. Baumert, Hepatitis C virus co-opts innate immunity component for lipid droplet formation, *J. Hepatol.* 59 (2013) 1118-1120.
- [99] S. Xu, R. Pei, M. Guo, Q. Han, J. Lai, Y. Wang, C. Wu, Y. Zhou, M. Lu, X. Chen, Cytosolic phospholipase A₂ γ is involved in hepatitis C virus replication and assembly, *J. Virol.* 86 (2012) 13025-13037.

- [100] Y. Rouille, F. Helle, D. Delgrange, P. Roingeard, C. Voisset, E. Blanchard, S. Belouzard, J. McKeating, A.H. Patel, G. Maertens, T. Wakita, C. Wychowski, J. Dubuisson, Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus, *J. Virol.* 80 (2006) 2832-2841.
- [101] K. Ishihara, K. Tachibana, A. Kuroda, A. Terakawa, S. Baba, S. Kanai, S. Akiba, Triacylglycerol deposition with group IVC phospholipase A₂ expression in oleate- and linoleate-stimulated Huh-7 hepatocytes, *Biol. Pharm. Bull.* 34 (2011) 191-196.
- [102] R. Zechner, P.C. Kienesberger, G. Haemerle, R. Zimmermann, A. Lass, Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores, *J. Lipid. Res.* 50 (2009) 3-21.
- [103] T.O. Eichmann, M. Kumari, J.T. Haas, R.V. Farese, Jr., R. Zimmermann, A. Lass, R. Zechner, Studies on the substrate and stereo/regioselectivity of adipose triglyceride lipase, hormone-sensitive lipase, and diacylglycerol-O-acyltransferases, *J. Biol. Chem.* 287 (2012) 41446-41457.
- [104] Z. Chamoun, F. Vacca, R.G. Parton, J. Gruenberg, PNPLA3/adiponutrin functions in lipid droplet formation, *Biol. Cell* 105 (2013) 219-233.
- [105] S.G. Young, R. Zechner, Biochemistry and pathophysiology of intravascular and intracellular lipolysis, *Genes Dev.* 27 (2013) 459-484.
- [106] H. Ruhanen, J. Perttila, M. Holtta-Vuori, Y. Zhou, H. Yki-Jarvinen, E. Ikonen, R. Kakela, V.M. Olkkonen, PNPLA3 mediates hepatocyte triacylglycerol remodeling, *J. Lipid Res.* 55 (2014) 739-746.
- [107] M. V. Winstead, J. Balsinde, and E. A. Dennis. Calcium-independent phospholipase A₂: structure and function. *Biochim. Biophys. Acta* 1488 (2000) 28-39.

- [108] J. Balsinde, and E. A. Dennis. Function and inhibition of intracellular calcium-independent phospholipase A₂. *J. Biol. Chem.* 272 (1997) 16069-16072
- [109] J. Balsinde, M.A. Balboa, E.A. Dennis, Antisense inhibition of group VI Ca²⁺-independent phospholipase A₂ blocks phospholipid fatty acid remodeling in murine P388D₁ macrophages, *J. Biol. Chem.* 272 (1997) 29317-29321.
- [110] J. Balsinde, I.D. Bianco, E.J. Ackermann, K. Conde-Frieboes, E.A. Dennis, Inhibition of calcium-independent phospholipase A₂ prevents arachidonic acid incorporation and phospholipid remodeling in P388D₁ macrophages, *Proc. Natl. Acad. Sci. U.S.A.* 92 (1995) 8527-8531.
- [111] C.S. Beckett, K. Pennington, J. McHowat, Activation of MAPKs in thrombin-stimulated ventricular myocytes is dependent on Ca²⁺-independent PLA₂, *Am. J. Physiol.* 290C (2006) 1350-1354.
- [112] X. Han, H. Cheng, D.J. Mancuso, R.W. Gross, Caloric restriction results in phospholipid depletion, membrane remodeling, and triacylglycerol accumulation in murine myocardium, *Biochemistry* 43 (2004) 15584-15594.
- [113] D.J. Mancuso, X. Han, C.M. Jenkins, J.J. Lehman, N. Sambandam, H.F. Sims, J. Yang, W. Yan, K. Yang, K. Green, D.R. Abendschein, J.E. Saffitz, R.W. Gross, Dramatic accumulation of triglycerides and precipitation of cardiac hemodynamic dysfunction during brief caloric restriction in transgenic myocardium expressing human calcium-independent phospholipase A₂γ, *J. Biol. Chem.* 282 (2007) 9216-9227.
- [114] K.J. Moore, F.J. Sheedy, E.A. Fisher, Macrophages in atherosclerosis: a dynamic balance, *Nat. Rev. Immunol.* 13 (2013) 709-721.

- [115] S.A. Karabina, S. Gora, R. Atout, E. Ninio, Extracellular phospholipases in atherosclerosis, *Biochimie* 92 (2010) 594-600.
- [116] R.S. Rosenson, E. Hurt-Camejo, Phospholipase A₂ enzymes and the risk of atherosclerosis, *Eur. Heart J.* 33 (2012) 2899-2909.
- [117] H. Sato, R. Kato, Y. Isogai, G. Saka, M. Ohtsuki, Y. Taketomi, K. Yamamoto, K. Tsutsumi, J. Yamada, S. Masuda, Y. Ishikawa, T. Ishii, T. Kobayashi, K. Ikeda, R. Taguchi, S. Hatakeyama, S. Hara, I. Kudo, H. Itabe, M. Murakami, Analyses of group III secreted phospholipase A₂ transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis, *J. Biol. Chem.* 283 (2008) 33483-33497.
- [118] S.A. Karabina, I. Brocheriou, G. Le Naour, M. Agrapart, H. Durand, M. Gelb, G. Lambeau, E. Ninio, Atherogenic properties of LDL particles modified by human group X secreted phospholipase A₂ on human endothelial cell function, *FASEB J.* 20 (2006) 2547-2549.
- [119] E. Hurt-Camejo, G. Camejo, P. Sartipy, Phospholipase A₂ and small, dense low-density lipoprotein, *Curr. Opin. Lipidol.* 11 (2000) 465-471.
- [120] D. Gao, M.Z. Ashraf, N.S. Kar, D. Lin, L.M. Sayre, E.A. Podrez, Structural basis for the recognition of oxidized phospholipids in oxidized low density lipoproteins by class B scavenger receptors CD36 and SR-BI, *J. Biol. Chem.* 285 (2010) 4447-4454.
- [121] J. Kzhyshkowska, C. Neyen, S. Gordon, Role of macrophage scavenger receptors in atherosclerosis, *Immunobiology* 217 (2012) 492-502.
- [122] D.M. Curfs, S.A. Ghesquiere, M.N. Vergouwe, I. van der Made, M.J. Gijbels, D.R. Greaves, J.S. Verbeek, M.H. Hofker, M.P. de Winther, Macrophage secretory

phospholipase A₂ group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology, *J. Biol. Chem.* 283 (2008) 21640-21648.

[123] K. Hanasaki, T. Ono, A. Saiga, Y. Morioka, M. Ikeda, K. Kawamoto, K. Higashino, K. Nakano, K. Yamada, J. Ishizaki, H. Arita, Purified group X secretory phospholipase A₂ induced prominent release of arachidonic acid from human myeloid leukemia cells, *J. Biol. Chem.* 274 (1999) 34203-34211.

[124] C.R. Wooton-Kee, B.B. Boyanovsky, M.S. Nasser, W.J. de Villiers, N.R. Webb, Group V sPLA₂ hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation, *Arterioscler. Thromb. Vasc. Biol.* 24 (2004) 762-767.

[125] S.A. Ghesquiere, M.J. Gijbels, M. Anthonsen, P.J. van Gorp, I. van der Made, B. Johansen, M.H. Hofker, M.P. de Winther, Macrophage-specific overexpression of group IIa sPLA₂ increases atherosclerosis and enhances collagen deposition, *J. Lipid Res.* 46 (2005) 201-210.

[126] N.R. Webb, M.A. Bostrom, S.J. Szilvassy, D.R. van der Westhuyzen, A. Daugherty, F.C. de Beer, Macrophage-expressed group IIA secretory phospholipase A₂ increases atherosclerotic lesion formation in LDL receptor-deficient mice, *Arterioscler. Thromb. Vasc. Biol.* 23 (2003) 263-268.

[127] P. Sartipy, G. Bondjers, E. Hurt-Camejo, Phospholipase A₂ type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes, *Arterioscler. Thromb. Vasc. Biol.* 18 (1998) 1934-1941.

- [128] C. Flood, M. Gustafsson, R.E. Pitas, L. Arnaboldi, R.L. Walzem, J. Boren, Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100, *Arterioscler. Thromb. Vasc. Biol.* 24 (2004) 564-570.
- [129] J.K. Hakala, K. Oorni, M.O. Pentikainen, E. Hurt-Camejo, P.T. Kovanen, Lipolysis of LDL by human secretory phospholipase A₂ induces particle fusion and enhances the retention of LDL to human aortic proteoglycans, *Arterioscler. Thromb. Vasc. Biol.* 21 (2001) 1053-1058.
- [130] L.J. den Hartigh, R. Altman, J.E. Norman, J.C. Rutledge, Postprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFκB, *Am. J. Physiol.* 306 (2014) H109-H120.
- [131] J.E. Feig, B. Hewing, J.D. Smith, S.L. Hazen, E.A. Fisher, High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies, *Circ. Res.* 114 (2014) 205-213.
- [132] Y. Ishimoto, K. Yamada, S. Yamamoto, T. Ono, M. Notoya, K. Hanasaki, Group V and X secretory phospholipase A₂s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions, *Biochim. Biophys. Acta* 1642 (2003) 129-138.
- [133] B. Jian, M. de la Llera-Moya, Y. Ji, N. Wang, M.C. Phillips, J.B. Swaney, A.R. Tall, G.H. Rothblat, Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors, *J. Biol. Chem.* 273 (1998) 5599-5606.

- [134] R.M. Stoekenbroek, J.J. Kastelein, G.K. Hovingh, Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A₂ antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs, *Curr. Opin. Lipidol.* 24 (2013) 459-466.
- [135] S.J. Nicholls, J.J. Kastelein, G.G. Schwartz, D. Bash, R.S. Rosenson, M.A. Cavender, D.M. Brennan, W. Koenig, J.W. Jukema et al., Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial, *J. Am. Med. Assoc.* 311 (2014) 252–262.
- [136] J.A. Menéndez, R. Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, *Nat. Rev. Cancer* 7 (2007) 763-777.
- [137] C.R. Santos, A. Schulze, Lipid metabolism in cancer, *FEBS J.* 279 (2012) 2610-2623.
- [138] K.F. Scott, M. Sajinovic, J. Hein, S. Nixdorf, P. Galettis, W. Liauw, P. de Souza, Q. Dong, G.G. Graham, P.J. Russell, Emerging roles for phospholipase A₂ enzymes in cancer, *Biochimie* 92 (2010) 601-610.
- [139] S. Li, T. Zhou, C. Li, Z. Dai, D. Che, Y. Yao, L. Li, J. Ma, X. Yang, G. Gao, High metastatic astric and breast cancer cells consume oleic acid in an AMPK dependent manner, *PLoS One* 9 (2014) e97330.
- [140] X. Li, H. Jiang, L. Qu, W. Yao, H. Cai, L. Chen, T. Peng, Hepatocyte nuclear factor 4alpha and downstream secreted phospholipase A₂ GXIIB regulate production of infectious hepatitis C virus, *J. Virol.* 88 (2014) 612-627.

- [141] M. Guan, L. Qu, W. Tan, L. Chen, C.W. Wong, Hepatocyte nuclear factor-4 alpha regulates liver triglyceride metabolism in part through secreted phospholipase A₂ GXIIB, *Hepatology* 53 (2011) 458-466.
- [142] S. Tsimikas, L.D. Tsironis, A.D. Tselepis, New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A₂ in atherosclerosis and cardiovascular disease, *Arterioscler. Thromb. Vasc. Biol.* 27 (2007) 2094-2099.
- [143] H. Noto, M. Hara, K. Karasawa, O.N. Iso, H. Satoh, M. Togo, Y. Hashimoto, Y. Yamada, T. Kosaka, M. Kawamura, S. Kimura, K. Tsukamoto, Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress, *Arterioscler. Thromb. Vasc. Biol.* 23 (2003) 829-835.
- [144] P. Turunen, J. Jalkanen, T. Heikura, H. Puhakka, J. Karppi, K. Nyysönen, S. Ylä-Herttuala, Adenovirus-mediated gene transfer of Lp-PLA₂ reduces LDL degradation and foam cell formation in vitro, *J. Lipid Res.* 45 (2004) 1633-1639.
- [145] R.L. Wilensky, C.H. Macphee, Lipoprotein-associated phospholipase A₂ and atherosclerosis, *Curr. Opin. Lipidol.* 20 (2009) 415-420.
- [146] C.J. Packard, D.S. O'Reilly, M.J. Caslake, A.D. McMahon, I. Ford, J. Cooney, C.H. Macphee, K.E. Suckling, M. Krishna, F.E. Wilkinson, A. Rumley, G.D. Lowe, Lipoprotein-associated phospholipase A₂ as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group, *N. Engl. J. Med.* 343 (2000) 1148-1155.
- [147] D.M. Stafforini, G.A. Zimmerman, Unraveling the PAF-AH/Lp-PLA₂ controversy, *J. Lipid Res.* (in press).

[148] J.A. Shayman, R. Kelly, J. Kollmeyer, Y. He, A. Abe, Group XV phospholipase A₂, a lysosomal phospholipase A₂, *Prog. Lipid Res.* 50 (2011) 1-13.

Figure Legends

Figure 1. LD synthesis from the cytosolic face of the smooth endoplasmic reticulum membranes. The essential role of cPLA₂α role in inducing a positive membrane curvature is indicated in step 3. Lysophospholipids are highlighted in pink, and phosphatidic acid in green. All other phospholipids are shown in blue. For further details see text.

Figure 2. Sequential role of PLA₂ forms in LD formation. iPLA₂ regulates neutral lipid synthesis first; then, cPLA₂α regulates formation of the organelle itself. Whether there is cross-talk between the two PLA₂s is not known. For details see text.




Figure 1.




Figure 2.

TABLE I - PLA₂ Classification and Roles in LD Formation

Group	Subgroup	Trivial name	MW (kDa)	Type of enzyme	Other catalytic activities	Role in LD formation	Ref.
I	A	-	13 - 15	Secreted, Ca ²⁺ dependent	-	-	-
	B	Pancreatic PLA ₂	13 - 15	Secreted, Ca ²⁺ dependent	-	-	-
II	A	-	13 - 15	Secreted, Ca ²⁺ dependent	-	EA: Promotes LD formation OE: Induces foam cell formation	48 125
	B	-	13 - 15	Secreted, Ca ²⁺ dependent	Inactive	-	-
	C	-	15	Secreted, Ca ²⁺ dependent	-	-	-
	D	-	14 - 15	Secreted, Ca ²⁺ dependent	-	-	-
	E	-	14 - 15	Secreted, Ca ²⁺ dependent	-	-	-
	F	-	16 - 17	Secreted, Ca ²⁺ dependent	-	-	-
III	-	-	15-18; 55	Secreted, Ca ²⁺ dependent	-	OE: Promotes foam cell formation	117
IV	A	cPLA ₂ α	85	Cytosolic, Ca ²⁺ dependent	Lysophospholipase, transacylase	KD: decreases LD formation	20, 46, 52 53
	B	cPLA ₂ β	114	Cytosolic, Ca ²⁺ dependent	-	-	-
	C	cPLA ₂ γ	64	Cytosolic, Ca ²⁺ dependent	Lysophospholipase	-	-
	D	cPLA ₂ δ	91	Cytosolic, Ca ²⁺ dependent	-	-	-
	E	cPLA ₂ ε	95	Cytosolic, Ca ²⁺ dependent	-	-	-
	F	cPLA ₂ ζ	95	Cytosolic, Ca ²⁺ dependent	-	-	-
V			14	Secreted, Ca ²⁺ dependent	-	EA: Promotes foam cell formation	50, 124
VI	A	iPLA ₂ , iPLA ₂ β	88-90	Ca ²⁺ independent	PLA ₁ , lysophospholipase, PAF acetylhydrolase, and transacylase	OE: Accumulation of TAG in myocardium.	113
	B	iPLA ₂ γ	88	Ca ²⁺ independent	-	-	-
VII	A	PAF-AH (lipoprotein associated PLA ₂)	45	Secreted, Ca ²⁺ independent	Lipase, esterase and transacetylase	OE: Attenuation of foam cell formation.	144

	B	PAF-AH (II)	40	Intracellular, Ca ²⁺ independent		-	-
VIII	A	PAF-AH Ib (α 1)	26	Ca ²⁺ independent	-	-	-
	B	PAF-AH Ib (α 2)	26	Ca ²⁺ independent	-	-	-
IX	-	Conodipine-M	14	Secreted, Ca ²⁺ dependent	-	-	-
X	-	-	14	Secreted, Ca ²⁺ dependent	-	EA: promotes foam cell formation. EA/OE: induces LD formation.	49, 118 51 122
XI	A	-	12.4	Secreted, Ca ²⁺ dependent	-	-	-
	B	-	12.9	Secreted, Ca ²⁺ dependent	-	-	-
XII	A	-	19	Secreted, Ca ²⁺ dependent	-	-	-
	B	-	19.7	Secreted, Ca ²⁺ dependent	Inactive	KO: Increases hepatic TAG	140
XIII	-	-	<10	Secreted, Ca ²⁺ dependent	-	-	-
XIV	-	-	13-19	Secreted, Ca ²⁺ dependent	-	-	-
XV		Lysosomal PLA ₂	45	Lysosomal, Ca ²⁺ independent	Transacylase	KO: Foam cell formation	148
XVI		Adipose-specific PLA ₂	18	Ca ²⁺ dependent/ Independent	PLA ₁	-	

*KO: Knock out; KD: Knock down (siRNA); OE: Overexpression; EA: External addition